Detailed Information

Cited 29 time in webofscience Cited 31 time in scopus
Metadata Downloads

Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Full metadata record
DC Field Value Language
dc.contributor.authorLim, Sung-Nam-
dc.contributor.authorJoo, Young-Don-
dc.contributor.authorLee, Kyoo-Hyung-
dc.contributor.authorKim, Dae-Young-
dc.contributor.authorLee, Je-Hwan-
dc.contributor.authorLee, Jung-Hee-
dc.contributor.authorChi, Hyun-Sook-
dc.contributor.authorYun, Sung-Cheol-
dc.contributor.authorLee, Won Sik-
dc.contributor.authorLee, Sang Min-
dc.contributor.authorPark, Seonyang-
dc.contributor.authorKim, Inho-
dc.contributor.authorSohn, Sang Kyun-
dc.contributor.authorMoon, Joon Ho-
dc.contributor.authorRyoo, Hun-Mo-
dc.contributor.authorBae, Sung Hwa-
dc.contributor.authorHyun, Myung Soo-
dc.contributor.authorKim, Min Kyoung-
dc.contributor.authorKim, Hyeoung Joon-
dc.contributor.authorYang, Deok-Hwan-
dc.contributor.authorEom, Hyeon-Seok-
dc.contributor.authorLee, Gyeong-Won-
dc.contributor.authorJung, Chul Won-
dc.contributor.authorWon, Jong-Ho-
dc.contributor.authorKim, Hawk-
dc.contributor.authorLee, Jae-Hoon-
dc.contributor.authorShin, Ho-Jin-
dc.contributor.authorJang, Dae-Young-
dc.date.available2020-02-28T07:43:44Z-
dc.date.created2020-02-06-
dc.date.issued2015-11-
dc.identifier.issn0361-8609-
dc.identifier.urihttps://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/9976-
dc.description.abstractThe effects of imatinib plus chemotherapy were assessed in 87 patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib was administered continuously, starting from the eighth day of remission induction chemotherapy, then through five courses of consolidation or until allogeneic hematopoietic cell transplantation (HCT). Patients who were not transplanted were maintained on imatinib for 2years. Eighty-two patients (94.3%) achieved complete remission (CR). Among these 82 CR patients, 40 experienced recurrence of leukemia. The 5-year relapse free survival (RFS) rate and overall survival (OS) rates were 39.0% and 33.4%, respectively. In total, 56 patients underwent allogeneic HCT in first CR. The 5-year cumulative incidence of relapse and OS rate of them were 59.1% and 52.6%, respectively. Six of seven patients who were maintained on imatinib after completion of consolidation relapsed and the median time of RFS was 40.7months. In total patient, cumulative molecular CR rate was 88.5% and median time of molecular CR duration was 13months. Initial imatinib dose intensity was significantly associated with median CR duration (P<0.0001), and overall survival (P=0.002). During the initial phase of treatment of patients with Ph+ ALL, it is important to maintain imatinib dose intensity. Am. J. Hematol. 90:1013-1020, 2015. (c) 2015 Wiley Periodicals, Inc.-
dc.language영어-
dc.language.isoen-
dc.publisherWILEY-BLACKWELL-
dc.relation.isPartOfAMERICAN JOURNAL OF HEMATOLOGY-
dc.subjectACUTE LYMPHOCYTIC-LEUKEMIA-
dc.subjectCHRONIC MYELOID-LEUKEMIA-
dc.subjectBCR-ABL-
dc.subjectCOMPLETE REMISSION-
dc.subjectADULT PATIENTS-
dc.subjectHYPER-CVAD-
dc.subjectNILOTINIB-
dc.subjectMESYLATE-
dc.subjectTRIAL-
dc.titleLong-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia-
dc.typeArticle-
dc.type.rimsART-
dc.description.journalClass1-
dc.identifier.wosid000363463600012-
dc.identifier.doi10.1002/ajh.24137-
dc.identifier.bibliographicCitationAMERICAN JOURNAL OF HEMATOLOGY, v.90, no.11, pp.1013 - 1020-
dc.identifier.scopusid2-s2.0-84944551048-
dc.citation.endPage1020-
dc.citation.startPage1013-
dc.citation.titleAMERICAN JOURNAL OF HEMATOLOGY-
dc.citation.volume90-
dc.citation.number11-
dc.contributor.affiliatedAuthorLee, Jae-Hoon-
dc.type.docTypeArticle-
dc.subject.keywordPlusACUTE LYMPHOCYTIC-LEUKEMIA-
dc.subject.keywordPlusCHRONIC MYELOID-LEUKEMIA-
dc.subject.keywordPlusBCR-ABL-
dc.subject.keywordPlusCOMPLETE REMISSION-
dc.subject.keywordPlusADULT PATIENTS-
dc.subject.keywordPlusHYPER-CVAD-
dc.subject.keywordPlusNILOTINIB-
dc.subject.keywordPlusMESYLATE-
dc.subject.keywordPlusTRIAL-
dc.relation.journalResearchAreaHematology-
dc.relation.journalWebOfScienceCategoryHematology-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
Files in This Item
There are no files associated with this item.
Appears in
Collections
의과대학 > 의학과 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Jae Hoon photo

Lee, Jae Hoon
College of Medicine (Department of Medicine)
Read more

Altmetrics

Total Views & Downloads

BROWSE